# US 2019/0316075 A1 · Microfluidic system and method of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316075 A1
- Document ID: US20190316075A1
- Status: Published application
- Kind: A1
- Application number: 16/462,047
- Filed: 2017-11-17
- Published: 2019-10-17
- Earliest claimed: 2016-11-18
- Assignees: New York Stem Cell Foundation, Inc.
- Applicants: New York Stem Cell Foundation, Inc.
- Inventors: Scott Noggle; Stephen Chang
- Web page: https://patentgrep.com/patent/US20190316075A1

## CPC

- C12M 23/16: {Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093)}
- C12M 47/04: {Cell isolation or sorting (purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04)}
- B01L 3/5027: {by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- C12M 23/58: {Reaction vessels connected in series or in parallel (combinations of bioreactors with other apparatus, C12M43/00)}
- C12M 41/48: {Automatic or computerized control (automatic analysis G01N35/00)}
- F16K 99/0003: {Constructional types of microvalves; Details of the cutting-off member}
- G01N 15/02: Investigating particle size or size distribution (by measuring osmotic pressure G01N7/10; investigating sedimentation of particle suspensions G01N15/04; investigating individual particles G01N15/10)
- B01L 2200/0647: Handling flowable solids, e.g. microscopic beads, cells, particles
- F16K 2099/0086: {Medical applications}
- G01N 15/01: specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N15/05)
- G01N 2015/1006: {for cytology}
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- F16K: VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING {(devices for emptying and evacuating the excess liquid in valves or conduits F16L55/07)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention concerns an integrated microfluidic system that utilizes microfluidic chip technology to receive a patient sample including cells, expand the cells, reprogram the expanded cells and then store the reprogrammed cells in a microfluidic chip. These microfluidic chips with stored reprogrammed cells may then be used in scenarios of genetic differentiation into specific cell types. Overall this system and workflow is suitable as a hospital based device that will allow the generation of iPSCs from every isolating patient for downstream diagnostic or therapeutic use.

## Claims

### Claim 1

A microfluidic system for processing a biological sample comprising:
a) one or more microfluidic units operable to process the sample, the processing comprising:
i) isolating cells from the sample;
ii) optionally expanding the isolated cells to produce a population of expanded cells;
iii) reprogramming the isolated cells or the expanded cells; and
iv) storing cells from one or more of (i), (ii) or (iii); and
b) one or more computer memory modules containing instructions for controlling one or more of processes (i)-(iv); and
c) one or more computer processor modules configured to execute the instructions.

### Claim 2 (depends on 1)

The system of claim 1, wherein the system is further operable to perform an analysis of the isolated cells of (i), the expanded cells of (ii), the reprogrammed cells of (iii), or a combination thereof.

### Claim 3 (depends on 1)

The system of claim 1, wherein the one or more microfluidic units is further operable to differentiate the iPSC to produce a cell of a desired cell type.

### Claim 4 (depends on 3)

The system of claim 3, wherein the system is further operable to perform an analysis on the cell of the desired cell type.

### Claim 5 (depends on 3)

The system of claim 3, wherein the system is further operable to store the cell of the desired cell type.

### Claim 6 (depends on 1)

The system of claim 1, the isolated cells are somatic cells.

### Claim 7 (depends on 1)

The system of claim 1, wherein the isolated cells are white blood cells.

### Claim 8 (depends on 1)

The system of claim 1, wherein the sample is selected from whole blood, blood fractions, serum, plasma, urine, sweat, lymph, feces, ascites, seminal fluid, sputum, nipple aspirate, post-operative seroma, wound drainage fluid, saliva, synovial fluid, ascites fluid, bone marrow aspirate, cerebrospinal fluid, nasal secretions, amniotic fluid, bronchoalveolar lavage fluid, pleural effusion, peripheral blood mononuclear cells, skin cells, total white blood cells, lymph node cells, spleen cells, skin biopsy, cord blood, cord tissue and tonsil cells.

### Claim 9 (depends on 2)

The system of claim 2, wherein analysis comprises image analysis, cell number analysis, cell surface marker analysis, cytokine secretion analysis, cell morphology analysis, polymerase chain reaction (PCR) analysis, sequence analysis, DNA analysis, RNA analysis, gene expression profiling, proteome analysis, metabolome analysis, immunoassays, nuclear exclusion analysis, or a combination thereof.

### Claim 10 (depends on 1)

The system of claim 1, wherein storing cells comprises freezing the cells.

### Claim 11 (depends on 1)

The system of claim 1, further comprising a graphical user interface.

### Claim 12 (depends on 1)

The system of claim 1, wherein the system comprises at least two, three, or four microfluidic units.

### Claim 13 (depends on 12)

The system of claim 12, wherein the microfluidic units are wirelessly or electrically coupled.

### Claim 14 (depends on 12)

The system of claim 12, wherein the microfluidic units are fluidly coupled.

### Claim 15 (depends on 1)

The system of claim 1, wherein the microfluidic units are disposed within a unitary housing.

### Claim 16 (depends on 1)

The system of claim 1, wherein the cells are stored on a microfluidic chip.

### Claim 17 (depends on 1)

The system of claim 1, wherein the system further comprises a storage unit for storing the cells at −80° C. or less.

### Claim 18 (depends on 1)

The system of claim 1, wherein the system is further operable to process and store sample data associated with stored cells.

### Claim 19 (depends on 1)

The system of claim 1, wherein cells are stored as master and working cell banks.

### Claim 20 (depends on 1)

The system of claim 1, wherein reprogramming cells comprises contacting the cells with one or more nuclear reprogramming factors.

### Claim 21 (depends on 21)

The system of claim 21, wherein the nuclear reprogramming factor is a polynucleotide, polypeptide, or small molecule.

### Claim 22 (depends on 3)

The system of claim 3, wherein differentiation comprises contacting the cells with one or more differentiation factors.

### Claim 23 (depends on 22)

The system of claim 22, wherein the one or more differentiator factors is a polypeptide, a vector-free gene regulator oligonucleotide, a microRNA, a messenger RNA encoding a differentiation factor, or an oligonucleotide that affects expression of a differentiation factor by the cell.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method for processing a biological sample comprising:
a) applying the sample to the system according to any of claims 1-23; and
b) processing the sample with the system, the processing comprising:
i) isolating cells from the sample;
ii) optionally expanding the isolated cells to produce a population of expanded cells;
iii) reprogramming the isolated or expanded cells; and
iv) storing cells from any of (i), (ii) or (iii), thereby processing the biological sample.

### Claim 25 (depends on 24)

The method of claim 24, further comprising differentiating the reprogrammed cells to produce a cell of a desired cell type.

### Claim 26 (depends on 25)

The method of claim 25, further comprising analyzing the isolated cells of (i), the expanded cells of (ii), the reprogrammed cells of (iii), the cell of a desired cell type, or a combination thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein analysis comprises image analysis, cell number analysis, cell morphology analysis, polymerase chain reaction (PCR) analysis, sequence analysis, DNA analysis, RNA analysis, gene expression profiling, proteome analysis, metabolome analysis, immunoassays, nuclear exclusion analysis, or a combination thereof.

### Claim 28 (depends on 24)

The method of claim 24, further comprising obtaining the sample from a subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the subject has or is at risk of having a disease or disorder.

### Claim 30 (depends on 29)

The method of claim 29, further comprising treating the subject with a cell processed by the system.

### Claim 31 (depends on 28)

The method of claim 28, wherein the subject is a healthy individual.

### Claim 32 (depends on 30)

The method of claim 30, further comprising storing cells from the sample or cells processed from the sample until the subject is diagnosed with a disease or disorder.

### Claim 33 (depends on 32)

The method of claim 32, further comprising utilizing the stored cells to treat the disease or disorder.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method of treating a disease or disorder in a subject comprising:
a) obtaining a sample from the subject;
b) applying the sample to the system according to any of claims 1-23;
c) processing the sample with the system, the processing comprising:
i) isolating cells from the sample;
ii) optionally expanding the isolated cells to produce a population of expanded cells;
iii) reprogramming the isolated or expanded cells;
iv) differentiating the reprogrammed cells to a desired cell type; and
v) storing cells from any of (i), (ii), (iii) or (iv); and
d) administering the subject a cell of any of (i)-(v), thereby treating the disease or disorder in the subject.

### Claim 35 (depends on 34)

The method of claim 34, further comprising analyzing the isolated cells of (i), the expanded cells of (ii), the reprogrammed cells of (iii), the cell of a desired cell type, or a combination thereof.

### Claim 36 (depends on 35)

The method of claim 35, wherein analysis comprises image analysis, cell number analysis, cell morphology analysis, polymerase chain reaction (PCR) analysis, sequence analysis, DNA analysis, RNA analysis, gene expression profiling, proteome analysis, metabolome analysis, immunoassays, nuclear exclusion analysis, or a combination thereof.

### Claim 37 (depends on 34)

The method of claim 34, further comprising diagnosing the disease or disorder in the subject.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A pharmaceutical composition comprising cells processed by the system of any of claims 1-23, or a cellular fraction thereof.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A cell bank comprising one or more populations of cells processed by the system of any of claims 1-23.

### Claim 40 (depends on 39)

The cell bank of claim 39, wherein each population is derived from a different sample.

### Claim 41 (depends on 1)

The system of claim 1, wherein the system comprises at least one, two, three, or four microfluidic units in operable communication with a secondary device.

### Claim 42 (depends on 41)

The system of claim 41, wherein the secondary device is a cell culture device, a bioreactor, a diagnostic device, an imaging device, a sequencing device, a nucleic acid amplification device, a nucleic acid or protein isolation device, a genome analysis device, a cell isolation device, a cellular fractionation device, or any combination thereof.

### Claim 43 (depends on 41)

The system of claim 41, wherein the secondary system is a non-microfluidic device operable of performing one or more of (i)-(iv).
